16th May 2008 14:23
|
For immediate release |
16 May 2008 |
ALLIANCE PHARMA PLC
("Alliance Pharma" or "the Company")
Isprelor Update
Alliance Pharma plc (AIM: APH), the speciality pharmaceutical company, today announces an update on the outlook for Isprelor, its development product for the induction of labour.
Following discussions yesterday with the European regulatory authorities, the Company is re-evaluating the development plan for Isprelor. It now appears likely that results of the Phase III trials completed last year will be inadequate, alone, to support the application for registration.
As a result the Company is re-assessing what additional work needs to be done, but it is now unlikely that the filing for registration will take place before 2011.
For further information:
|
Alliance Pharma plc |
+ 44 (0) 1249 466966
|
|
John Dawson, Chief Executive |
|
|
Richard Wright, Finance Director |
|
|
www.alliancepharma.co.uk |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000
|
|
Mark Court / Rebecca Skye Dietrich |
|
|
Numis Securities |
+ 44 (0) 20 7260 1000
|
|
David Poutney / Michael Meade |
Related Shares:
Alliance Pharma